EMA recommendation triggers $40M payment for blood disorder drug

Incyte and Novartis' blood disorder drug ruxolitinib was recommended for approval by the European Medicines Agency's Committee for Medicinal Products for Human Use an enlarged spleen therapy in myelofibrosis patients. The recommendation will bring Incyte a $40 million milestone payment from Novartis. The drug is called Jakavi in Europe and Jakafi in the U.S., where it was approved by the FDA in November.

View Full Article in:

Bloomberg Businessweek · Pharmaceutical Business Review Online

Published in Brief:

SmartBrief Job Listings for Health Care

Job Title Company Location
Health Care Exchange Account Manager
Kaiser Permanente
San Diego, CA
Director, Health Plan Claims Operations
Group Health Cooperative
Seattle, WA
Stop Loss Sales Executive
Blue Cross Blue Shield of MA
Boston, MA
Field Representative-Oklahoma and Kansas
National Rural Electric Cooperative Association (NRECA)
Multiple Locations, SL_Multiple Locations
Vice President, Idaho Regional Director
PacificSource
Boise, ID